Document is current
Any future updates will be listed below
-
Authors
Pan, Richard
Ren, Jingwei
Chen, Xinyue https://orcid.org/0000-0003-0264-1488
Flores, Luis F. https://orcid.org/0000-0002-0422-4680
Gonzalez, Rachel V. L.
Adonnino, Andre Antonio
Lofts, Brandon
Waldo, Jennifer https://orcid.org/0000-0002-3310-9331
Halmai, Julian
Devinsky, Orrin https://orcid.org/0000-0003-0044-4632
Fink, Kyle https://orcid.org/0000-0002-0235-5038
Liu, X. Shawn https://orcid.org/0000-0002-2799-2519
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH134519)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS126185)
- License Information
-
More Information
Article History
Received: 14 October 2024
Accepted: 25 November 2025
First Online: 10 December 2025
Competing interests
: O.D. has equity in Epitor Therapeutics, Regel Therapeutics, Ajna Biosciences, Blackrock Neurotech, ConnectRN, Tevard Therapeutics, and PhiFund Ventures. K.F. is a SAB member for Epitor Therapeutics. X.S.L. is a co-founder of Epitor Therapeutics. The remaining authors declare no competing interests.
